Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
S. Damodaran, C. C. O'Sullivan, A. Elkhanany, I. C. Anderson, M. Barve, S. Blau, M. A. Cherian, J. A. Peguero, M. P. Goetz, P. V. Plourde, D. J. Portman, H. C.F. Moore
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2'. Together they form a unique fingerprint.